Lyndon C. Wright

TL;DR: In conclusion, repeated administration was well-tolerated but produced relatively low plasma concentrations of trans-resveratrol, despite the high doses and short dosing interval used.

TL;DR: From the Department of Research and Development, S Mamede do Coronado, Portugal (Dr Nunes, Dr Almeida, Mr Rocha, Mr Fernandes-Lopes, Ms Loureiro, Dr Wright, Dr Vaz-da-Silva, Dr Soares-da,Silva); Institute of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto; and 4Health Consulting, Cantanhede, Portugal.

TL;DR: The rate of absorption of trans-resveratrol following an oral 400 mg single-dose was significantly delayed by the presence of food, as reflected by Cmax and tmax, but the extent of absorption was not affected and AUC0- yen was close to the bioequivalence standard.

TL;DR: Despite its short elimination half-life, opicapone markedly and sustainably inhibited erythrocyte S-COMT activity making it suitable for a once daily regimen.

TL;DR: Opicapone was well-tolerated and presented dose-proportional kinetics, and sustained inhibition of erythrocyte soluble COMT activity was demonstrated, providing a basis for further clinical development of opicapone.